CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Trial Assessing Neoadjuvant Therapy With FEC 100 Followed by Taxotere® (Docetaxel) Plus Vectibix® (Panitumumab) in Patients With Operable, HR and Her-2 Negative Breast Cancer. TVA Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00933517
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:32.145205+00:00
Published At: 2014-03-21T00:00:00+00:00
Record Updated At: 2014-03-21
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Pathological Response Rate"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2014-03-21"
protocolSection.identificationModule.nctId: "NCT00933517"
protocolSection.identificationModule.officialTitle: "Phase II Trial Assessing Neoadjuvant Therapy With FEC 100 Followed by Taxotere\u00ae (Docetaxel) Plus Vectibix\u00ae (Panitumumab) in Patients With Operable, HR and Her-2 Negative Breast Cancer. TVA Study"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.